Breast Cancer– tag –
-
New Series: Untangling Cancer Worries: Organ-by-Organ Basics at a Glance — Episode 4: Breast Cancer—What to Know First After Noticing a Lump (The Testing Pathway)
“Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer searches can quickly become overwhelming. “Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer s... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Breast cancer is one of the most information-heavy topics in women... -
How Respiratory Viral Infections May Alter Metastatic Risk in Breast Cancer: Latest Evidence and Practical Guidance
Respiratory viral infections may silently reshape metastatic risk in breast cancer survivors. Recent epidemiology and mechanistic studies converge on a practical question: what should clinicians change tomorrow morning? Here is the evide... -
Catchup News: HER2 ADC Special Report Part 2｜IP Strategies, Global Competition, and the Road Ahead
In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ... -
Catchup News: HER2 ADC Special Report Part 1｜The Rise of Enhertu and Pharmacological Differentiation Driving the Second ADC Boom
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergo...
1